Tag Archives: AcelRx Pharmaceuticals

La Jolla Pharma Steps In With Better Offer, Wins Tetraphase Bidding War

It’s common for antibiotics developers to run into financial trouble these days but what’s unusual is seeing a bidding war erupt for one of them. The competition for Tetraphase Pharmaceuticals now has a new winner: La Jolla Pharmaceutical. San Diego-based La Jolla (NASDAQ: LJPC) has pledged to pay Tetraphase shareholders $43 million in cash now […]

Melinta Expands Antibiotics Lineup With $39M Tetraphase Acquisition

Melinta Therapeutics and Tetraphase Pharmaceuticals, two antibiotics companies that have struggled separately, will now see if they have better luck together. Morristown, NJ-based Melinta has reached a deal to acquire Tetraphase (NASDAQ: TTPH) for $39 million in cash up front. Tetraphase shareholders could earn up to $16 million more if the Watertown, MA-based biotech’s sole […]

Posted in Boston blog main, Boston top stories, National blog main, New York, New York blog main, New York top stories | Tagged AcelRx Pharmaceuticals, Antibiotic, Biotech, deals, Deerfield Management, eravacycline, La Jolla Pharmaceutical, Life Sciences, Melinta Therapeutics, Tetraphase Pharmaceuticals | Comments Off

Bio Roundup: Light For Spark, California Drug Law, IPO Queue & More

In a year of tragedies across the U.S., natural or otherwise, it seemed this week was California’s turn. Fueled by high winds, low humidity, and ample dry vegetation, fires swept through several towns across the state and, as of this writing, have barely been contained. With our minds on friends and loved ones affected by […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Wisconsin blog main, Wisconsin top stories | Tagged AbbVie, abemaciclib, Abingworth, AcelRx Pharmaceuticals, Affordable Care Act, Allena Pharmaceuticals, amazon, AnaptysBio, Ardelyx, Biotech, Broad Institute, Broad Institute of Harvard and MIT, Deerfield Management, Eli Lilly, FDA, Flexion Therapeutics, Food and Drug Administration, Fred Hutchinson Cancer Research Center, Gene Therapy, IPO, Jerry Brown, KalVista Pharmaceuticals, Life Sciences, luxturna, Merck, Mission Bay, OrthoPediatrics, Spark Thearpeutics, Spero Therapeutics, Turnstone Biologics, VirionHealth | Comments Off

Many Biotechs Need Inside IPO Help, But Selecta Is An Extreme Case

Because public investors have had a more discerning attitude toward biotech IPOs this year, insiders have had to step up to help their companies go public. One extreme example is Selecta Biosciences, which just priced its offering late Tuesday with its pre-IPO investors likely buying around 60 percent of the shares. Selecta, of Watertown, MA, […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, San Francisco blog main | Tagged AcelRx Pharmaceuticals, Back Bay Life Science Advisors, BeiGene, Cancer Prevention Pharmaceuticals, Celgene, Cempra, Corvus Pharmaceuticals, deals, Dicerna Therapeutics, Gemphire Therapeutics, Intellia Therapeutics, IPOs, Jonathan Gertler, Life Sciences, Merus, Oncobiologics, Patrick Soon-Shiong, PhaseRx, ProteoStasis Therapeutics, RA Capital Management, Rajeev Shah, Renaissance Capital, Selecta Biosciences, Spring Bank Pharmaceuticals, Syros Pharmaceuticals, VC | Comments Off

Foresite Capital Closes $100M Fund for Late-Stage Biotechs

Biotech venture capital isn’t what it used to be, but there’s still money to invest in healthcare. Now one biotech investment firm just starting out has found $100 million to plow into “late-stage” companies. Foresite Capital Management, a San Francisco- and New York-based firm founded by Jim Tananbaum in 2011, said today it has officially […]

Posted in National blog main, New York blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged AcelRx Pharmaceuticals, Biotech, Dorothy Margolskee, Finances, Foresite Capital Management, Intarcia Therapeutics, Jim Tananbaum, Keryx Pharmaceuticals, Life Sciences, people, Prospect Venture Partners, Puma Biotechnology, Solta Medical, Tarsa Therapeutics | Comments Off

Exclusive: Skyline Ventures Cuts Partners, Postpones Fundraising

Skyline Ventures, one of the high-profile venture firms in the U.S. biotech and medical device business over the past 15 years, has let go three of its six partners and postponed plans to raise a new venture fund, Xconomy has learned. Skyline, which has offices in Palo Alto, CA, Waltham, MA, and Stamford, CT, raised […]

Posted in Boston blog main, Boston top stories, National, National blog main, National top stories, San Francisco blog main, San Francisco top stories | Tagged AcelRx Pharmaceuticals, Biotech, California Public Employees' Retirement System, Canaan Partners, CMEA Capital, Genocea Biosciences, GlaxoSmithKline, KAI Pharmaceuticals, Kleiner Perkins Caufield & Byers, Life Sciences, MAP Pharmaceuticals, Medivance, Merck, NimbleGen Systems, NovaCardia, OVP Venture Partners, people, Prospect Venture Partners, Scale Venture Partners, Sirtris Pharmaceuticals, Skyline Ventures, Sofinnova Ventures, startups, Steve Burrill, Steve Hoffman, Sutro Biopharma, Tetraphase Pharmaceuticals, VC, Versant Ventures, Xenoport | 2 Comments

AcelRx Gets $40M in IPO

Redwood City, CA-based AcelRx Pharmaceuticals (NASDAQ: ACRX) said today it has priced its initial public offering. The company sold 8 million shares at $5 apiece, meaning it raised gross proceeds of $40 million. That’s far less than the $12 to $14 per share price range AcelRx had forecasted on Jan. 31. The company, a developer […]

Posted in National briefs, San Francisco, San Francisco briefs | Tagged AcelRx Pharmaceuticals, Biotech, Canaccord Genuity, Cowen & Co., deals, Finances, JMP Securities, Life Sciences, Piper Jaffray | Comments Off

AcelRx Pharmaceuticals Receives $8,000,800 New Financing

Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=5751e8cb-4813-4721-9a75-5ba6b774a53b&Preview=1 Date 9/21/2010 Company Name AcelRx Pharmaceuticals Mailing Address 575 Chesapeake Drive Redwood City, CA 94063 Company Description The company is developing a novel drug-device therapy for the treatment of breakthrough pain. Website http://www.acelrx.com/ Transaction Type Debt Transaction Amount $8,000,800 Transaction Round Undisclosed Proceeds Purposes Proceeds purposes were not disclosed. SEC regulatory […]

Posted in San Francisco, San Francisco VentureDeal VC | Tagged AcelRx Pharmaceuticals, SanFranciscoVC, Undisclosed | Comments Off

AcelRx Pharmaceuticals Obtains $14,814,000 New Round

Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=840efaea-729a-42aa-8d38-3bae8be0499f&Preview=1 Date 12/31/2009 Company Name AcelRx Pharmaceuticals Mailing Address 575 Chesapeake Drive Redwood City, CA 94063 Company Description The company is developing a novel drug-device therapy for the treatment of breakthrough pain. Website http://www.acelrx.com/ Transaction Type Venture Equity Transaction Amount $14,814,000 Transaction Round Undisclosed Proceeds Purposes Proceeds purposes were not disclosed. M&A […]

Posted in San Francisco, San Francisco VentureDeal VC | Tagged AcelRx Pharmaceuticals, Alta Partners, SanFranciscoVC, Three Arch Partners | Comments Off

Tag Archives: AcelRx Pharmaceuticals

Archives

Meta